Skip to main content
SpringerLink
Log in

LINC00963 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma by Interacting with miR-10a to Upregulate SKA1 Expression

  • Original Article
  • Published:
Applied Biochemistry and Biotechnology Aims and scope Submit manuscript

Abstract

Long non-coding RNA (lncRNA) is associated with a large number of tumor cellular functions together with chemotherapy resistance in a variety of tumors. LINC00963 was identified to regulate the malignant progression of various cancers. However, whether LINC00963 affects drug resistence in esophageal squamous cell carcinoma (ESCC) and the relevant molecular mechanisms have never been reported. This study aims to investigate the effect of LINC00963 on cisplatin resistance in ESCC. After detecting the level of LINC00963 in human esophageal squamous epithelial cells (HET-1 A), ESCC cells (TE-1) and cisplatin resistant cells of ESCC (TE-1/DDP), TE-1/DDP cell line and nude mouse model that interfered with LINC00963 expression were established. Then, the interaction among LINC00963, miR-10a, and SKA1 was clarified by double luciferase and RNA immunoprecipitation (RIP) assays. Meanwhile, the biological behavior changes of TE-1/DDP cells with miR-10a overexpression or SKA1 silencing were observed by CCK-8, flow cytometry, scratch, Transwell, and colony formation tests. Finally, the biological function of the LINC00963/SKA1 axis was elucidated by rescue experiments. LINC00963 was upregulated in TE-1 and TE-1/DDP cell lines. LINC00963 knockdown inhibited SKA1 expression of both cells and impaired tumorigenicity. Moreover, LINC00963 has a target relationship with miR-10a, and SKA1 is a target gene of miR-10a. MiR-10a overexpression or SKA1 silencing decreased the biological activity of TE-1/DDP cells and the expression of SKA1. Furthermore, SKA1 overexpression reverses the promoting effect of LINC00963 on cisplatin resistance of ESCC. LINC00963 regulates TE-1/DDP cells bioactivity and mediates cisplatin resistance through interacting with miR-10a and upregulating SKA1 expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data Availability

Not applicable.

References 

  1. Bollschweiler, E., Plum, P., & Monig, S. P. (2017). Current and future treatment options for esophageal cancer in the elderly. Expert Opinion on Pharmacotherapy, 18(10), 1001–1010. https://doi.org/10.1080/14656566.2017.1334764

    Article  CAS  PubMed  Google Scholar 

  2. Lam, A. K. (2020). Introduction: Esophageal squamous cell carcinoma-current status and future advances. Methods in Molecular Biology, 2129, 1–6. https://doi.org/10.1007/978-1-0716-0377-2_1

    Article  CAS  PubMed  Google Scholar 

  3. Domper Arnal, M. J., Ferrandez Arenas, A., & Lanas Arbeloa, A. (2015). Esophageal cancer: Risk factors, screening and endoscopic treatment in western and eastern countries. World Journal of Gastroenterology, 21(26), 7933–7943. https://doi.org/10.3748/wjg.v21.i26.7933

    Article  PubMed  PubMed Central  Google Scholar 

  4. Hu, D., Li, Z., Li, X., & Fu, H. (2019). SKA1 overexpression is associated with the prognosis of esophageal squamous cell carcinoma and regulates cell proliferation and migration. International Journal of Molecular Medicine, 44(5), 1971–1978. https://doi.org/10.3892/ijmm.2019.4343

    Article  CAS  PubMed  Google Scholar 

  5. Akiyama, Y., Iwaya, T., Endo, F., Chiba, T., Takahara, T., Otsuka, K., Nitta, H., Koeda, K., Mizuno, M., Kimura, Y., & Sasaki, A. (2018). Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma. Surgical Endoscopy, 32(1), 391–399. https://doi.org/10.1007/s00464-017-5688-5

    Article  PubMed  Google Scholar 

  6. Hirata, H., Niida, A., Kakiuchi, N., Uchi, R., Sugimachi, K., Masuda, T., Saito, T., Kageyama, S. I., Motomura, Y., Ito, S., Yoshitake, T., Tsurumaru, D., Nishimuta, Y., Yokoyama, A., Hasegawa, T., Chiba, K., Shiraishi, Y., Du, J., Miura, F., Morita, M., Toh, Y., Hirakawa, M., Shioyama, Y., Ito, T., Akimoto, T., Miyano, S., Shibata, T., Mori, M., Suzuki, Y., Ogawa, S., & Ishigami, K., Mimori, K. (2021). The evolving genomic Landscape of esophageal squamous cell Carcinoma under Chemoradiotherapy. Cancer Research, 81(19), 4926–4938. https://doi.org/10.1158/0008-5472.CAN-21-0653

    Article  CAS  PubMed  Google Scholar 

  7. Bridges, M. C., Daulagala, A. C., & Kourtidis, A. (2021). LNCcation: lncRNA localization and function. Journal of Cell Biology, 220(2). https://doi.org/10.1083/jcb.202009045

  8. Evans, J. R., Feng, FY&, & Chinnaiyan, A. M. (2016). The bright side of dark matter: lncRNAs in cancer. J Clin Invest, 126(8), 2775–2782. https://doi.org/10.1172/JCI84421

    Article  PubMed  PubMed Central  Google Scholar 

  9. Meng, Q., Li, Z., & Pan, J. (2020). Long noncoding RNA DUXAP8 regulates proliferation and apoptosis of ovarian cancer cells via targeting miR-590-5p. Human Cell, 33(4), 1240–1251. https://doi.org/10.1007/s13577-020-00398-8

    Article  CAS  PubMed  Google Scholar 

  10. Luo, Y., Zheng, S., Wu, Q., Wu, J., Zhou, R., Wang, C., Wu, Z., Rong, X., Huang, N., Sun, L., Bin, J., Liao, Y., & Shi, M. (2021). Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy, 17(12), 4083–4101. https://doi.org/10.1080/15548627.2021.1901204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Xue, S. T., Zheng, B., Cao, S. Q., Ding, J. C., Hu, G. S., Liu, W., & Chen, C. (2022). Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis. Molecular Cancer, 21(1), 69. https://doi.org/10.1186/s12943-022-01539-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cui, Y., Zhang, C., Ma, S., Li, Z., Wang, W., Li, Y., Ma, Y., Fang, J., Wang, Y., Cao, W., & Guan, F. (2021). RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research : Cr, 40(1), 294. https://doi.org/10.1186/s13046-021-02096-1

    Article  CAS  PubMed Central  Google Scholar 

  13. Tang, J., Xu, H., Liu, Q., Zheng, J., Pan, C., Li, Z., Wen, W., Wang, J., Zhu, Q., & Wang, Z. (2021). LncRNA LOC146880 promotes esophageal squamous cell carcinoma progression via miR-328-5p/FSCN1/MAPK axis. Aging (Albany NY), 13(10), 14198–14218. https://doi.org/10.18632/aging.203037

    Article  CAS  PubMed  Google Scholar 

  14. Niu, Y., Guo, Y., Li, Y., Shen, S., Liang, J., & Guo, W. (2022). LncRNA GATA2-AS1 suppresses esophageal squamous cell carcinoma progression via the mir-940/PTPN12 axis. Experimental Cell Research, 416(2), 113130. https://doi.org/10.1016/j.yexcr.2022.113130

    Article  CAS  PubMed  Google Scholar 

  15. Huang, J., Li, J., Li, Y., Lu, Z., Che, Y., Mao, S., Lei, Y., Zang, R., Zheng, S., Liu, C., Wang, X., Li, N., Sun, N., & He, J. (2019). Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. Cancer Lett, 459, 86–99. https://doi.org/10.1016/j.canlet.2019.05.03

    Article  CAS  PubMed  Google Scholar 

  16. Zhang, H., Pan, E., Zhang, Y., Zhao, C., Liu, Q., & Pu, Y. (2022). LncRNA RPL34-AS1 suppresses the proliferation, migration and invasion of esophageal squamous cell carcinoma via targeting miR-575/ACAA2 axis. Bmc Cancer, 22(1), 1017. https://doi.org/10.1186/s12885-022-10104-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Yu, T., Zhao, Y., Hu, Z., Li, J., Chu, D., Zhang, J., Li, Z., Chen, B., Zhang, X., Pan, H., Li, S., Lin, H., Liu, L., Yan, M., & He, X. (2017). MetaLnc9 facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR pathway. Cancer Research, 77(21), 5782–5794. https://doi.org/10.1158/0008-5472.CAN-17-0671

    Article  CAS  PubMed  Google Scholar 

  18. Wu, J. H., Tian, X. Y., An, Q. M., Guan, X. Y., & Hao, C. Y. (2018). LINC00963 promotes hepatocellular carcinoma progression by activating PI3K/AKT pathway. European Review for Medical and Pharmacological Sciences, 22(6), 1645–1652. https://doi.org/10.26355/eurrev_201803_14574

    Article  PubMed  Google Scholar 

  19. Jiao, H., Jiang, S., Wang, H., & Li, Y. (2018). Upregulation of LINC00963 facilitates melanoma progression through miR-608/NACC1 pathway and predicts poor prognosis. Biochemical and Biophysical Research Communications, 504(1), 34–39. https://doi.org/10.1016/j.bbrc.2018.08.115

    Article  CAS  PubMed  Google Scholar 

  20. Hu, R., Xu, B., Ma, J., Li, L., Zhang, L., Wang, L., Zhu, J., Guo, T., Zhang, H., & Wang, S. (2023). LINC00963 promotes the malignancy and metastasis of lung adenocarcinoma by stabilizing Zeb1 and exosomes-induced M2 macrophage polarization. Molecular Medicine, 29(1), 1. https://doi.org/10.1186/s10020-022-00598-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zuo, W., Zhou, K., Deng, M., Lin, Q., Yin, Q., Zhang, C., Zhou, J., & Song, Y. (2020). LINC00963 facilitates acute myeloid leukemia development by modulating miR-608/MMP-15. Aging (Albany NY), 12(19), 18970–18981. https://doi.org/10.18632/aging.103252

    Article  CAS  PubMed  Google Scholar 

  22. Xie, Z., Zhong, C., Shen, J., Jia, Y., & Duan, S. (2022). LINC00963: A potential cancer diagnostic and therapeutic target. Biomedicine & Pharmacotherapy, 150, 113019. https://doi.org/10.1016/j.biopha.2022.113019

    Article  CAS  Google Scholar 

  23. Arai, T., Okato, A., Kojima, S., Idichi, T., Koshizuka, K., Kurozumi, A., Kato, M., Yamazaki, K., Ishida, Y., Naya, Y., Ichikawa, T., & Seki, N. (2017). Regulation of spindle and kinetochore-associated protein 1 by antitumor miR-10a-5p in renal cell carcinoma. Cancer Science, 108(10), 2088–2101. https://doi.org/10.1111/cas.13331

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Song, G. Q., He, T. L., Ji, K. J., Duan, Y. M., Zhang, J. W., & Hu, G. Q. (2022). SKA1/2/3 is a biomarker of poor prognosis in human hepatocellular carcinoma. Frontiers in Oncology, 12, 1038925. https://doi.org/10.3389/fonc.2022.1038925

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sun, W., Yao, L., Jiang, B., & Guo, L. (2014). Spindle and kinetochore-associated protein 1 is overexpressed in gastric cancer and modulates cell growth. Molecular and Cellular Biochemistry, 391(1–2), 167–174. https://doi.org/10.1007/s11010-014-1999-1

    Article  CAS  PubMed  Google Scholar 

  26. Chen, C., Guo, Q., Song, Y., & Xu, G. (2020). SKA1/2/3 serves as a biomarker for poor prognosis in human lung adenocarcinoma. Transl Lung Cancer Res, 9(2), 218–231. https://doi.org/10.21037/tlcr.2020.01.20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Chen, Y., Zhao, J., Jiao, Z., Wang, W., Wang, D., Yu, X., Shi, Z., Ge, N., Pan, Q., Xia, J., Niu, W., Zhao, R., Zhang, X., & Du, W. (2018). SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma. Bmc Cancer, 18(1), 1240. https://doi.org/10.1186/s12885-018-5119-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Dong, D., Mu, Z., Wei, N., Sun, M., Wang, W., Xin, N., & Shao, Y. (2019). Long non-coding RNA ZFAS1 promotes proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-10a/SKA1 pathway. Biomedicine & Pharmacotherapy, 111, 917–925. https://doi.org/10.1016/j.biopha.2018.12.143

    Article  CAS  Google Scholar 

  29. Shen, D., Zhao, H. Y., Gu, A. D., Wu, Y. W., Weng, Y. H., Li, S. J., Song, J. Y., Gu, X. F., Qiu, J., & Zhao, W. (2021). miRNA-10a-5p inhibits cell metastasis in hepatocellular carcinoma via targeting SKA1. Kaohsiung Journal of Medical Sciences, 37(9), 784–794. https://doi.org/10.1002/kjm2.12392

    Article  CAS  PubMed  Google Scholar 

  30. Xiao, J., & Yu, H. (2019). LINC00339 promotes growth and invasiveness of hepatocellular carcinoma by the miR-1182/SKA1 pathway. Onco Targets Ther, 12, 4481–4488. https://doi.org/10.2147/OTT.S207397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Yamada, Y., Arai, T., Kojima, S., Sugawara, S., Kato, M., Okato, A., Yamazaki, K., Naya, Y., Ichikawa, T., & Seki, N. (2018). Anti-tumor roles of both strands of the miR-455 duplex: Their targets SKA1 and SKA3 are involved in the pathogenesis of renal cell carcinoma. Oncotarget, 9(42), 26638–26658. https://doi.org/10.18632/oncotarget.25410

    Article  PubMed  PubMed Central  Google Scholar 

  32. Chang, A., & Wang, P. (2022). LINC00963 may be Associated with a poor prognosis in patients with cervical Cancer. Medical Science Monitor, 28, e935070. https://doi.org/10.12659/MSM.935070

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. He, J., Wang, Z., Wang, Y., Liu, F., Fu, L., Jiang, X., Wang, P., Chen, H., Hu, M., & Cai, H. (2023). A systematic review and meta-analysis of long noncoding RNA 00963 expression and prognosis and clinicopathological characteristic in human cancers. Pathology, Research and Practice, 242, 154291. https://doi.org/10.1016/j.prp.2022.154291

    Article  CAS  PubMed  Google Scholar 

  34. Gai, Q., & Guo, W. (2021). EZH2-mediated long-chain non-coding RNA LINC00963 promotes proliferation and invasion of glioma cells through inhibiting p21 expression. J BUON, 26(2):380–387.

  35. Zhang, N., Zeng, X., Sun, C., Guo, H., Wang, T., Wei, L., Zhang, Y., & Zhao, J. (2019). LncRNA LINC00963 promotes tumorigenesis and radioresistance in breast Cancer by sponging mir-324-3p and inducing ACK1 expression. Mol Ther Nucleic Acids, 18, 871–881. https://doi.org/10.1016/j.omtn.2019.09.033

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Hou, M., & Li, C. (2021). LINC00963/miR-4458 regulates the effect of oxaliplatin in gastric cancer by mediating autophagic flux through targeting of ATG16L1. Scientific Reports, 11(1), 20951. https://doi.org/10.1038/s41598-021-98728-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wu, X., Sui, Z., Zhang, H., & Wang, Y. (2020). Integrated Analysis of lncRNA-Mediated ceRNA Network in Lung Adenocarcinoma. Frontiers in Oncology, 10, 554759. https://doi.org/10.3389/fonc.2020.554759

    Article  PubMed  PubMed Central  Google Scholar 

  38. Wu, Z., Wang, W., Wang, Y., Wang, X., Sun, S., Yao, Y., & Zhang, Y. (2020). Long noncoding RNA LINC00963 promotes breast cancer progression by functioning as a molecular sponge for microRNA-625 and thereby upregulating HMGA1. Cell Cycle, 19(5), 610–624. https://doi.org/10.1080/15384101.2020.1728024

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Ye, F., Xu, R., Ge, Y., Zheng, Y., Liu, X., & Deng, P. (2020). LINC00963 confers oncogenic properties in Glioma by regulating the miR-506/BCAT1 Axis. Cancer Manag Res, 12, 2339–2351. https://doi.org/10.2147/CMAR.S246332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Ghaemi, Z., & Mowla, S. J. (2023). Novel splice variants of LINC00963 suppress colorectal cancer cell proliferation via miR-10a/miR-143/miR-217/miR-512-mediated regulation of PI3K/AKT and Wnt/beta-catenin signaling pathways. Biochim Biophys Acta Gene Regul Mech, 1866(2), 194921. https://doi.org/10.1016/j.bbagrm.2023.194921

    Article  CAS  PubMed  Google Scholar 

  41. Yu, T., Liu, L., Li, J., Yan, M., Lin, H., Liu, Y., Chu, D., Tu, H., & Gu, A. (2015). MiRNA-10a is upregulated in NSCLC and may promote cancer by targeting PTEN. Oncotarget, 6(30), 30239–30250. https://doi.org/10.18632/oncotarget.4972

    Article  PubMed  PubMed Central  Google Scholar 

  42. Wang, C., & Yin, W. (2020). MicroRNA-10a promotes epithelial-to-mesenchymal transition and stemness maintenance of pancreatic cancer stem cells via upregulating the Hippo signaling pathway through WWC2 inhibition. Journal of Cellular Biochemistry, 121(11), 4505–4521. https://doi.org/10.1002/jcb.29716

    Article  CAS  PubMed  Google Scholar 

  43. Liu, L. J., Sun, X. Y., & Yang, C. X. (2021). MiR-10a-5p restrains the aggressive phenotypes of ovarian cancer cells by inhibiting HOXA1. Kaohsiung Journal of Medical Sciences, 37(4), 276–285. https://doi.org/10.1002/kjm2.12335

    Article  CAS  PubMed  Google Scholar 

  44. Liu, Y., Zhang, Y., Wu, H., Li, Y., Zhang, Y., Liu, M., & Li, X. (2017). miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and anoikis. Cell Death and Disease, 8(4), e2739. https://doi.org/10.1038/cddis.2017.61

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Mu, H., Xiang, L., Li, S., Rao, D., & Wang, S. (2019). MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A. Journal of Cellular Biochemistry, 120(4), 4987–4997. https://doi.org/10.1002/jcb.27774

    Article  CAS  PubMed  Google Scholar 

  46. Liu, Y., Wang, X., Jiang, X., Yan, P., Zhan, L., Zhu, H., Wang, T., & Wen, J. (2019). Tumor-suppressive microRNA-10a inhibits cell proliferation and metastasis by targeting Tiam1 in esophageal squamous cell carcinoma. Journal of Cellular Biochemistry, 120(5), 7845–7857. https://doi.org/10.1002/jcb.28059

    Article  CAS  PubMed  Google Scholar 

  47. Zhu, H., & Du, F. (2021). Restoration of circPSMC3 sensitizes gefitinib-resistant esophageal squamous cell carcinoma cells to gefitinib by regulating miR-10a-5p/PTEN axis. Cell Biology International, 45(1), 107–116. https://doi.org/10.1002/cbin.11473

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work is supported by the Natural Science Foundation of Shandong Province, No. ZR2020QH194.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China

    Dongxin Hu, Anqun Ma, Hongda Lu, Zhen Gao, Yue Yu, Jiaming Fan, Shang Liu & Yancheng Wang

  2. Department of Gastroenterology and Hepatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324, Jing Wu Road, Huaiyin District, Jinan, Shandong, 250021, China

    Mingyan Zhang

Authors
  1. Dongxin Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anqun Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongda Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhen Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yue Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiaming Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yancheng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mingyan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dongxin Hu, Anqun Ma,Hongda Lu, Zhen Gao, Yue Yu, Shang Liu, Yancheng Wang and Jiaming Fan contributed to the material preparation, data collection and analyses; Dongxin Hu and Mingyan Zhang contributed to the first draft; All authors contributed to the study conception and design, read and approved the final manuscript.

Corresponding author

Correspondence to Mingyan Zhang.

Ethics declarations

Ethical Approval

This study was approved by Shandong Provincial Hospital Affiliated to Shandong University Laboratory Animal Ethics Committee (No. 2019-020).

Consent to Participate

All authors have their consent to participate.

Consent for Publication

All authors have their consent to publish their work.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, D., Ma, A., Lu, H. et al. LINC00963 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma by Interacting with miR-10a to Upregulate SKA1 Expression. Appl Biochem Biotechnol (2024). https://doi.org/10.1007/s12010-024-04897-4

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12010-024-04897-4

Keywords

Search

Navigation